WS04.05Faecal colorectal cancer-associated toxins in adults with cystic fibrosis: preliminary analysis

IF 5.4 2区医学 Q1 RESPIRATORY SYSTEM

Journal of Cystic Fibrosis Pub Date : 2025-06-01 DOI:10.1016/j.jcf.2025.03.514

L.R. Caley , A. Fuentes Balaguer , D. Bottomley , C. Young , L. Wilkinson , C. Sears , P. Quirke , D.G. Peckham

{"title":"WS04.05Faecal colorectal cancer-associated toxins in adults with cystic fibrosis: preliminary analysis","authors":"L.R. Caley , A. Fuentes Balaguer , D. Bottomley , C. Young , L. Wilkinson , C. Sears , P. Quirke , D.G. Peckham","doi":"10.1016/j.jcf.2025.03.514","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><div>Cystic fibrosis is associated with an increased risk of colorectal cancer (CRC) owing to a complex interplay between CFTR dysfunction, inflammation, gut dysbiosis and diet. Toxigenic bacteria in the gut of non-CF individuals have been implicated in CRC pathogenesis. We explored the presence of CRC-associated toxins in a cohort of adults with CF (awCF).</div></div><div><h3>Methods</h3><div>Baseline faecal samples from 80 awCF were tested for the presence of the following CRC associated bacteria and toxins: <em>Fusobacterium nucleatum</em>, FadA, NusG, <em>Escherichia coli</em>, polyketide synthase (<em>pks</em>), <em>Bacteroides fragilis</em> (BF) and Enterotoxigenic BF (ETBF) by employing Taqman qPCR in triplicate. In a subgroup, changes pre and post elexacaftor/tezacaftor/ivacaftor (ETI) were analysed (n=25).</div></div><div><h3>Results</h3><div>At baseline, median age was 34 years (IQR 28, 40), ppFEV<sub>1</sub> 53 (IQR 39, 74) with 34% participants being female. Percentage of FadA, NusG, <em>pks</em>, ETBF positive samples are displayed in Table 1.</div><div>In the pre and post ETI group, median time between samples and duration of ETI were 15 (IQR 14, 18) and 6 months (IQR 3,10) respectively. Changes in CRC-associated bacteria/toxins are presented in Table 1. Descriptively, there was no change in CRC-associated bacteria and toxins post ETI.</div></div><div><h3>Conclusion</h3><div>CRC-associated bacteria and toxins are present in CF stool samples and do not appear to change with short-term ETI therapy. Analysis in ongoing, including comparing levels to controls and CRC samples, to elucidate clinical implications of these findings.</div><div>Funded by the UK CF Trust (SRC 012)</div></div>","PeriodicalId":15452,"journal":{"name":"Journal of Cystic Fibrosis","volume":"24 ","pages":"Pages S8-S9"},"PeriodicalIF":5.4000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cystic Fibrosis","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1569199325006101","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}

引用次数: 0

Abstract

Objectives

Cystic fibrosis is associated with an increased risk of colorectal cancer (CRC) owing to a complex interplay between CFTR dysfunction, inflammation, gut dysbiosis and diet. Toxigenic bacteria in the gut of non-CF individuals have been implicated in CRC pathogenesis. We explored the presence of CRC-associated toxins in a cohort of adults with CF (awCF).

Methods

Baseline faecal samples from 80 awCF were tested for the presence of the following CRC associated bacteria and toxins: Fusobacterium nucleatum, FadA, NusG, Escherichia coli, polyketide synthase (pks), Bacteroides fragilis (BF) and Enterotoxigenic BF (ETBF) by employing Taqman qPCR in triplicate. In a subgroup, changes pre and post elexacaftor/tezacaftor/ivacaftor (ETI) were analysed (n=25).

Results

At baseline, median age was 34 years (IQR 28, 40), ppFEV₁ 53 (IQR 39, 74) with 34% participants being female. Percentage of FadA, NusG, pks, ETBF positive samples are displayed in Table 1.

In the pre and post ETI group, median time between samples and duration of ETI were 15 (IQR 14, 18) and 6 months (IQR 3,10) respectively. Changes in CRC-associated bacteria/toxins are presented in Table 1. Descriptively, there was no change in CRC-associated bacteria and toxins post ETI.

Conclusion

CRC-associated bacteria and toxins are present in CF stool samples and do not appear to change with short-term ETI therapy. Analysis in ongoing, including comparing levels to controls and CRC samples, to elucidate clinical implications of these findings.

Funded by the UK CF Trust (SRC 012)

查看原文本刊更多论文

囊性纤维化成人粪便结直肠癌相关毒素：初步分析

由于CFTR功能障碍、炎症、肠道生态失调和饮食之间的复杂相互作用，囊性纤维化与结直肠癌（CRC）风险增加相关。非cf个体肠道中的产毒细菌与CRC的发病机制有关。我们在一组成年CF患者（awCF）中探讨了crc相关毒素的存在。方法采用Taqman qPCR方法，对80例awCF患者的基线粪便样本进行结直肠癌相关细菌和毒素检测：核梭杆菌、FadA、NusG、大肠杆菌、聚酮合成酶（pks）、脆弱拟杆菌（BF）和产肠毒素（ETBF）。在一个亚组中，分析了取牙器/取牙器/取牙器（ETI）前后的变化（n=25）。结果基线时，中位年龄为34岁（IQR 28,40）， ppFEV1 53岁（IQR 39,74）， 34%的参与者为女性。FadA、NusG、pks、ETBF阳性样本百分比见表1。在ETI前后组，样本间的中位时间和ETI持续时间分别为15个月（IQR 14, 18）和6个月（IQR 3,10）。crc相关细菌/毒素的变化见表1。描述性地说，ETI后crc相关细菌和毒素没有变化。结论CF粪便样本中存在crc相关细菌和毒素，且短期ETI治疗不会改变。正在进行的分析，包括与对照组和CRC样本的比较水平，以阐明这些发现的临床意义。由英国CF信托基金资助（SRC 012）

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Cystic Fibrosis 医学-呼吸系统

CiteScore

10.10

自引率

13.50%

发文量

1361

审稿时长

50 days

期刊介绍： The Journal of Cystic Fibrosis is the official journal of the European Cystic Fibrosis Society. The journal is devoted to promoting the research and treatment of cystic fibrosis. To this end the journal publishes original scientific articles, editorials, case reports, short communications and other information relevant to cystic fibrosis. The journal also publishes news and articles concerning the activities and policies of the ECFS as well as those of other societies related the ECFS.